Guideline-based lipid lowering approach in Asia-Pacific patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of a guideline-oriented approach to lipid management in patients hospitalized for Type I myocardial infarction. Participants will be randomly assigned to receive either an early intervention or standard care during their hospital stay, followed by a second phase where the control group will receive the intervention after six months. The intervention includes a 'Cholesterol score card' to facilitate communication between patients and their healthcare providers regarding lipid levels and adherence to therapy. The study is designed to reflect real-world clinical practices and enhance the generalizability of the findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age
* Admission for Type I myocardial infarction

Exclusion Criteria:

* LDL \<1.4mmol/L at baseline
* Unable to provide contact details of primary care physician/general practitioner
* Unable to provide written informed consent.
* Unlikely to survive \>12 months

Where it's running

• Illawarra Shoalhaven Local Health District
  Wollongong, New South Wales, Australia Recruiting
• Cairns & Hinterland Hospital & Health Service
  Cairns, Queensland, Australia Recruiting
• Monash Health
  Clayton, Victoria, Australia Recruiting
• Western Health
  Melbourne, Victoria, Australia Recruiting
• Affiliated Zhongshan Hospital of Dalian University
  Dalian, Liaoning, China Recruiting
• All India Institute of Medical Sciences
  New Delhi, India Recruiting

Study contacts

• Principal investigator: Stephen Nicholls, MBBS, PhD — Monash University
• Study coordinator: Julie Butters, BHSc, MBA
• Email: julie.butters@monash.edu
• Phone: 61 434679018

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients

  This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.

  Recruiting Fondazione Ricerca e Innovazione Cardiovascolare ETS · Milan, MI · NCT06535568

• Cardiovascular risk assessment for patients with lipid disorders in emergency care

  This study is testing a new way to help emergency room patients with high cholesterol lower their heart disease risk by providing better care compared to the usual treatment.

  Recruiting Phase 2 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT06488105

• Assessing heart disease risk using carotid ultrasound and stress tests

  This study is testing if combining a special ultrasound of the neck with stress tests can better identify people at risk for serious heart problems over the next three years.

  Recruiting at 5 sites Queen's University · Calgary, Alberta and 5 other locations · NCT05416385

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.